The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global inhalation anesthesia market size reached US$ 1.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 1.9 Billion by 2027, exhibiting a growth rate (CAGR) of 3.8% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Inhalation anesthesia refers to the anesthetic medications that are induced for maintaining the levels of general anesthesia and sedation in the body during surgery. Some of the commonly used inhalation anesthetics include nitrous oxide, desflurane, isoflurane and sevoflurane. These anesthetics are administered using a laryngeal face airway and a tracheal tube connected to a vaporizer. They are highly effective in small doses and can induce respiratory depression, reduce the arterial blood pressure and increase cerebral blood flow when used in unmoderated quantities. In comparison to the traditionally used intravenous variants, inhalation anesthesia does not accumulate in the body and aids in preventing excessive dosage, while promoting normal functioning of the patient.
The increasing prevalence of chronic medical disorders requiring surgical treatments is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to ailments, such as cardiovascular, neurological, respiratory and degenerative disorders, is providing a thrust to the market growth. Hospitals and other ambulatory healthcare centers are widely using sevoflurane and other ether-based inhalation anesthetic agents with low pungency and non-irritant odor for patients with asthma or sensitive air passages. Additionally, various technological advancements, such as the development of anesthesia recycling systems for extracting anesthetic compounds from hospital vents and operating rooms, are acting as other growth-inducing factors. In line with this, anesthesia manufacturers are also producing variants with enhanced compatibility and minimal side-effects to cater to the requirements of patients sensitive to anesthetic agents. Other factors, including significant improvements in the healthcare infrastructure, especially in the developing economies, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global inhalation anesthesia market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, Piramal Enterprises Ltd. and Troikaa Pharmaceuticals Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbvie Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, Piramal Enterprises Ltd. and Troikaa Pharmaceuticals Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at